ABSTRACT
Background Next generation sequencing (NGS) has increased detection sensitivity of intermediate chromosome copy number variations (CNV) consistent with chromosomal mosaicism. Recently, this methodology has found application in preimplantation genetic testing (PGT) of trophectoderm (TE) biopsies collected from IVF-generated human embryos. As a consequence, the detection rate of intermediate CNV states in IVF embryos has drastically increased, posing questions about the accuracy in identifying genuine mosaicism in highly heterogeneous biological specimens. The association between analytical values consistent with mosaicism and the reproductive potential of the embryo, as well as newborn’s chromosomal normalcy, have not yet been thoroughly determined.
Methods We conducted a multicentre, double-blinded, non-selection trial including 1,190 patients undergoing in a total of 1,337 IVF with preimplantation genetic testing for aneuploidies (PGT-A) treatment cycles. NGS was performed on clinical TE biopsies collected from blastocyst-stage embryos. All embryos were reported as euploid if all autosomes had a chromosomal copy number value below the threshold of 50% abnormal cells per sample. After embryo transfer, three comparative classes were analysed: uniformly euploid profiles (<20% aneuploid cells), putative low-degree mosaicism (20%-30% aneuploid cells) or putative moderate-degree mosaicism (30%-50% aneuploid cells). Primary outcome measure was live birth rate (LBR) per transfer and newborn’s karyotype.
Results LBR after transfer of uniformly euploid embryos, low-degree, and moderate-degree mosaic embryos were 43.4% (95% C.I. 38.9 - 47.9), 42.9% (95% C.I. 37.1 - 48.9) and 42% (95% C.I. 33.4 - 50.9), respectively. No difference was detected for this primary outcome between euploid and mosaic low/moderate categories (OR= 0.96; 95% CI 0.743 to 1.263; P=0.816). The non-inferiority endpoint was met as the confidence interval for the difference fell below the planned 7.5% margin (95% C.I. −5.7 - 7.3). Likewise, no statistically significant difference was observed comparing moderate versus low degree mosaic embryos (P=0.92). Neonatal karyotypes were also similar and no instances of mosaicism or uniparental disomies (UPDs) were detected in babies born following putative low or moderate-degree mosaic embryo transfer. Should the embryos with low or moderate-degree mosaic TE biopsies had been classified as chromosomally abnormal and thus discarded for clinical use, LBR per cycle would have decreased by 36% without any clinical benefit.
Conclusions This prospective non-selection trial provides substantial evidence that reporting and/or not transferring embryos with low/moderate-degree mosaicism for whole chromosomes have no clinical utility. Moreover, dismissing these embryos from clinical use has the counterproductive effect of reducing overall embryo availability, thus reducing the chance of successful outcome derived from an IVF treatment without any clinical benefit. (Funded by Igenomix; ClinicalTrials.gov number, NCT03673592)
Competing Interest Statement
Antonio Capalbo is a full time employee of Igenomix Italy. Maurizio Poli is a full time employee of Igenomix Italy. Laura Rienzi is the Scientific Director of GeneraLife IVF. She is Editor of Reproductive BioMedicine Online and has been Associate Editor of Human Reproduction Update. She has been the principal investigator of a study sponsored by Merck KGaA. She has received honoraria/consultation fees by Merck KGaA, MSD, Ferring, Ibsa, Cooper Surgical, Cook, Nterilizer, Fujifilm-Irvine Scientific, Medea and Universal clinics. She is partner/shareholder of Global Investment Clinics s.a'.r.l., Genera Health Care srl and Nterilizer, and has been of Flam srl. Laura Girardi is a full time employee of Igenomix Italy. Danilo Cimadomo is a full-time employee of GeneraLife IVF, where he is the Science and Research Manager. He received paid lectures from Fujifilm-Irvine Scientific. He received paid consultations from Merck KGaA. He is associate editor of the journal Human Reproduction Update". "He is part of the Executive Committee of the Italian Society of Embryology, Reproduction and Research (SIERR)", "he is the basic science officer of the special interest group in implantation and early pregnancy (SIGIEP) of the European Society of Human Reproduction and Embryology (ESHRE)". Francesca Benini is a senior embryologist at Demetra center, GeneraLife IVF. She received paid lectures from Fujifilm-Irvine Scientific. Carmen Rubio is a full-time employee of Igenomix Spain and Igenomix Foundation. Alberto Vaiarelli is a gynecologist at GeneraLife IVF. He received honoraria/paid lectures by Merck KGaA, Gedeon Richter and MSD. He is member of the executive committee of the Italian Society of Fertility and Sterility (SIFES). He is associate editor of the journal of assisted reproduction and genetics. Filippo Maria Ubaldi is the Scientific Director of GeneraLife IVF. He is the President of the Italian Society of Fertility and Sterility (SIFES). He has been the principal investigator of a study sponsored by Merck KGaA and by SR Farmaceutici. He has received honoraria/consultation fees by Merck KGaA, MSD, Ferring, Ibsa, Cooper Surgical, Cook, Nterilizer, Fujifilm-Irvine Scientific, Medea and Universal clinics. He is partner/shareholder of Global Investment Clinics s.a'.r.l., Genera Health Care srl and Nterilizer, and has been of Flam srl. Carlos Simon is the Head of the Scientific Advisory Board of Igenomix. All the other authors declared no competing interests.
Clinical Trial
NCT03673592
Funding Statement
This study as been founded by Igenomix, a company providing reproductive genetic services. Eva Hoffmann is recipient of European Research Council (ReCAP 724718) and Novo Nordisk Foundation grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was conducted in compliance with the International Conference on Harmonisation and the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of Clinica Valle Giulia, Rome (3 September 2018) and Humanitas Research Hospital Ethics Committee, Rozzano (with code 477/19).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data included in this manuscript are available as supplementary materials or upon authors' request.
